for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S

NOVOb.CO

Latest Trade

427.10DKK

Change

-7.65(-1.76%)

Volume

2,679,295

Today's Range

427.10

 - 

432.55

52 Week Range

331.70

 - 

467.90

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
434.75
Open
430.00
Volume
2,679,295
3M AVG Volume
47.80
Today's High
432.55
Today's Low
427.10
52 Week High
467.90
52 Week Low
331.70
Shares Out (MIL)
2,312.50
Market Cap (MIL)
774,146.10
Forward P/E
22.16
Dividend (Yield %)
2.13

Next Event

Novo Nordisk A/S at Barclays Global Healthcare Conference (Virtual)

Latest Developments

更多

Novo Nordisk Invests DKK 500 Million In Expanding Tablet Production Facilities In Denmark

Novo Nordisk Q4 Oper Profit At DKK 11.18 Bln

Novo Nordisk: Positive Opinion For Once-Weekly Sogroya

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry

Biotechnology & Drugs

Contact Info

Novo Alle 1

2880

Denmark

+45.44.448888

https://www.novonordisk.com/

Executive Leadership

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Jeppe Christiansen

Vice Chairman of the Board

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Maziar Mike Doustdar

Executive Vice President, International Operations

Key Stats

2.65 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2018

111.8K

2019

122.0K

2020

126.9K

2021(E)

132.7K
EPS (DKK)

2018

15.930

2019

16.380

2020

18.010

2021(E)

19.273
Price To Earnings (TTM)
23.71
Price To Sales (TTM)
6.10
Price To Book (MRQ)
15.60
Price To Cash Flow (TTM)
16.16
Total Debt To Equity (MRQ)
16.35
LT Debt To Equity (MRQ)
4.57
Return on Investment (TTM)
59.65
Return on Equity (TTM)
31.15

Latest News

Latest News

UPDATE 2-Diabetes drugmaker Novo Nordisk upbeat on 2021, sees Biden boost

Diabetes drugmaker Novo Nordisk forecast a rise in underlying sales and profit for 2021 on Wednesday and said it expected more Americans to get access to its drugs under the new Biden administration.

UPDATE 2-Novo Nordisk to start late-stage trial of semaglutide to treat Alzheimer's

Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test its semaglutide drug as a treatment for early Alzheimer's disease, it said on Wednesday.

UPDATE 1-Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal

Diabetes drug maker Novo Nordisk said on Friday it had agreed a $1.8 billion deal to acquire Emisphere Technologies, giving it control of a pill technology that it hopes will broaden sales to diabetics with an aversion to shots.

European stocks rise on upbeat forecasts from Pandora, Novo Nordisk

European stock markets gained on Friday on rosy earnings forecasts from retailers Pandora and Zalando as well as drugmaker Novo Nordisk, with investors keeping an eye out for signs of fresh U.S. stimulus.

UPDATE 2-Novo Nordisk tweaks outlook higher after pandemic sales hit

* Shares in Novo up almost 1% at 0800 GMT (Adds CFO and CEO quotes, details on stockpiling, share reaction)

BRIEF-HBM Healthcare Investments: Novo Nordisk Buys Portfolio Company

* NOVO NORDISK ACQUIRES HBM PORTFOLIO COMPANY CORVIDIA THERAPEUTICS FOR UP TO USD 2.1 BILLION IN CASH Source text for Eikon: Further company coverage: (Gdansk Newsroom)

UPDATE 2-Novo Nordisk's drug sales boosted by virus-related stockpiling

* Novo Nordisk's first-quarter profit and sales beat forecasts

UPDATE 2-Novo Nordisk sees slower 2020 growth with U.S. insulin prices pressured

* Novo expects 2020 sales to grow 3-6% in 2020 vs 6% last year

UPDATE 2-Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts

Novo Nordisk's new diabetes pill, Rybelsus, will be covered by Express Scripts Holding Co, one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday.

Novo Nordisk to offer free insulin to U.S. patients in immediate need

Novo Nordisk said on Thursday it would offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication, the rising price of which has attracted fierce criticism from lawmakers and regulators.

UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel

* Opg profit 12.9 bln Danish crowns vs expectations for 13.1 bln

UPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug

The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment.

UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.

Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

Novo Nordisk to cut insulin prices for some U.S. diabetics

Novo Nordisk said on Friday it would offer cheaper insulin to some U.S. diabetics in response to intense criticism over the high price of the medication and following similar moves by rivals Sanofi and Eli Lilly.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Novo Nordisk said on Thursday it has filed litigation in a Delaware district court against Mylan aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Novo Nordisk sued in Denmark for alleged market manipulation - media

Danish insulin-maker Novo Nordisk has been sued by investors demanding 11.8 billion Danish crowns ($1.8 billion) in compensation for the company's alleged market manipulation, Danish daily Borsen reported on Friday.

UPDATE 2-Novo Nordisk's new diabetes, obesity drugs lift sales outlook

* Upbeat about sales of its newest diabetes drug (Adds CEO quotes)

UPDATE 1-Diabetes drug maker Novo Nordisk buys pill factory in North Carolina

Novo Nordisk said on Tuesday it had bought a factory in North Carolina that would assist in manufacturing and packaging its new once-daily pill for treating type 2 diabetes.

CORRECTED-Oral Novo Nordisk diabetes drug poses no more heart risk than placebo -study

An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

Novo Nordisk and Gilead team up to test fatty liver disease treatment

Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up